Relationships between total metabolic tumor volume, rituximab pharmacokinetics, and patient outcome. (A) T_1/2β vs TMTV₀. (B) Rituximab exposure in induction cycle 1 (AUC₁) vs TMTV₀. ROC curves of the predictive value of AUC₁ for (C) PFS, (D) OS, and (E) PET4 metabolic response. Corresponding ROC AUCs were 0.73, 0.70, and 0.69, respectively. (F) AUC₁ in CMR vs non-CMR (8733 vs 9743 mg × h per liter; P = .001).